CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Contributers

Recommended Insights

Harnessing Big Data to Accelerate Clinical...

Leigh Householder, Executive Vice President,...

How Can Artificial Intelligence Improve...

Jorine Putter, Head of Advanced Analytics at...

The Evolving Internet of Things (IoT) in...

Jerry Power, Executive Director, Institute for...

Aligning IT with the Cadence of your Business

William Leonard, ScD, Chief Information Officer, MPI...

Data Governance is Relatively New to the...

William Phillips,SVP & CIO,University Health System

Future Predictive Analytics Solutions need...

Frank Wang, System Vice President, IDN Decision...

PCR Biosystems Launches a Range of IsoFast...

Jeremy Williams, Life Science Review

Navigo Proteins and Eleva Announce...

Jeremy Williams, Life Science Review

Harnessing Big Data to Accelerate Clinical...

Leigh Householder, Executive Vice President,...

How Can Artificial Intelligence Improve...

Jorine Putter, Head of Advanced Analytics at...

The Evolving Internet of Things (IoT) in...

Jerry Power, Executive Director, Institute for...

Aligning IT with the Cadence of your Business

William Leonard, ScD, Chief Information Officer, MPI...

Data Governance is Relatively New to the...

William Phillips,SVP & CIO,University Health System

Future Predictive Analytics Solutions need...

Frank Wang, System Vice President, IDN Decision...

PCR Biosystems Launches a Range of IsoFast...

Jeremy Williams, Life Science Review

Navigo Proteins and Eleva Announce...

Jeremy Williams, Life Science Review

Biopharma Start-Ups and the Development of New Drugs

Ulrich Geilinger, Venture Capitalist, HBM Partners AG
Tweet

Start-Ups in the Healthcare Sectors


In 2016, the U.S. spent 17.9 percent of GDP on healthcare. While other countries’ healthcare spend is lower, healthcare clearly is one of the largest sectors worldwide and a market with huge potential. It is no surprise, therefore, that start-ups and VC investors target innovative products and services for new medical applications.


One of the most profitable and but also very risky venture is the development of a new drug that ultimately need to be approved by the FDA before they can be marketed to US patients. Other sectors targeted by start-ups and VCs are medical technology, diagnostics including genomics, and most recently “Digital Health” applications.


Biopharma Start-Ups


Biopharma drug development, i.e. the development of new medications, has become a fruitful field for entrepreneurs and investors alike. As the development of a new drug to approval usually requires a few hundred million dollars spent over 10 or more years, any such start-up sooner or later turns to venture funds or other large investors for financing. Funding rounds with $50 million to $100 million are not uncommon. Once a new drug is approved by US FDA, the market potential usually is significant. The revenue potential of the 45 novel drugs approved by FDA in 2017 was estimated at close to $50 billion.


During the first half of 2018, 203 young biopharmaceutical companies in the U.S. received $7.6 billion of venture funding (out of $52 billion total venture capital invested). Thus, 2018 looks to be a record year for biopharma venture funding (and venture capital in general). In 2017, VCs invested $10.6 billion in biopharma companies up from $7.5 billion the year before. Similar amounts went to young companies in other healthcare sectors.


Large Pharma and Biopharma Start-Ups


The pharma industry today is still dominated by traditional large companies such as Pfizer, Novartis, Roche, Merck, J&J and the like. However, former start-up companies Gilead and Amgen have made it into the top 10 and were in 2017 ranked #7 and #10, respectively, in terms of worldwide pharma revenues.


Amgen, founded in 1980, was one of the first venture-funded biotechnology company. And, Gilead, founded a few years later in 1987, focused on anti-viral therapeutics.


These examples and many others show that breakthrough innovations in medical research often happen outside of the larger pharma companies even though the largest companies spend billions in R&D. Biotechnology drugs (proteins and antibodies as therapeutic medicines), cell therapies, therapeutic vaccines to combat cancer, so-called “orphan” drugs, immuno-oncology and other novel therapeutic approaches have all initially been pioneered by small companies.


Today, young and former start-up companies play a major role as developers of new drugs. Of the 45 new drugs approved by FDA in 2017, 27 or 60 percent were initially developed by young/ small companies! Many such start-ups then get bought by larger companies before they even reached revenue-stage. Others list on NASDAQ, which recently has been very receptive for biopharma companies with promising products in development.


Larger pharma companies today heavily rely on innovations from start-ups to “refreshen” their product range. They not only buy private and public biopharma companies on a regular basis, but also license drugs at all stages in development. Most large pharma companies also actively invest in young companies, usually through a corporate venture fund and have set-up incubators or university collaborations to get closer to the source of medical innovation.


Drug Development a Risky Business?


Overall, there are about 15’000 (!) of new drugs, i.e. new chemical molecules and new biologics, in development. Over 50 percent such potential new compounds are still in the discovery phase, i.e. have not been tested in humans.


These numbers show that only a very small fraction of drug projects succeed, making new drug development and related investments a highly risky proposition. Chances for success and good investor returns, however, can be improved if start-ups follow some of the recommendations below (see box). And two last pieces of advice: (1) Raise as much or more money than you need when conditions (internal and external) are favourable even if it means significant dilution for founders. Raise money at least one to two year before the next significant milestone. (2) If you receive a decent offer from a strategic partner to acquire your company, think twice before rejecting it, even though you believe that your product might be a “blockbuster” drug.


Weekly Brief

loading
Top 10 Bioanalytical Services Companies in Europe - 2021
Top 5 Bioanalytical Service Companies In Uk – 2021
Top 5 Emerging Bioanalytical Services Companies in UK and Europe - 2021
Top 10 Bioanalytical Services Companies in Europe - 2021
Top 5 Bioanalytical Service Companies In Uk – 2021
Top 5 Emerging Bioanalytical Services Companies in UK and Europe - 2021
> <
  • Bioanalytical Services Europe 2021

    Top Vendors

    Current Issue
  • Bioanalytical Services Europe 2021

    Top Vendors

    Current Issue

Read Also

How Small Pharma, Working Within a Global Pharma, Can Benefit From One Pharmacovigilance System

Mai Huang, M.D., Executive Director, Drug Safety and Pharmacovigilance, Avanir Pharmaceuticals
How Small Pharma, Working Within a Global Pharma, Can Benefit From One Pharmacovigilance System

From ideation to portfolio program: Innovation vs validation in early drug discovery

Carlos Pedraza, PhD. Director of CNS Biology, Alkermes
From ideation to portfolio program: Innovation vs validation in early drug discovery

Analytics as a competitive advantage takes 3 things - access, cleanliness, and action

Matt Southwick, Executive Director Clinical Systems and Analytical Reporting, Amgen
Analytics as a competitive advantage takes 3 things - access, cleanliness, and action

Analytical Considerations for Combination Products

Jennifer L. Riter, Sr. Director, Analytical Services, West Pharmaceutical Services, Inc.
Analytical Considerations for Combination Products
An open Innovation Approach Applied to the Pharmaceutical Industry

An open Innovation Approach Applied to the Pharmaceutical Industry

Federico Piutti, Innovation Manager, Bormioli Pharma
The Pharma Tech Landscape under the New Normal

The Pharma Tech Landscape under the New Normal

Dusan Ruzic, Director, External Manufacturing, Merck

How CMOs/CDMOs can Add Value for Pharma Companies

Ozgur Akbulut, Director - Global Divestments and Contract Manufacturing Lead, Takeda
How CMOs/CDMOs can Add Value for Pharma Companies

Avoiding the 'Shiny object' Trap of Digital Transformation

Timothy White, Vice President & Head of Global Digital Commercial, Teva Pharmaceuticals
Avoiding the 'Shiny object' Trap of Digital Transformation
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://bioanalytical-services-europe.lifesciencesreview.com/cxoinsight/biopharma-startups-and-the-development-of-new-drugs-nwid-318.html